WO2025109176 - OPTIMIZED SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS AND COMPOSITIONS COMPRISING THE SAME
National phase entry is expected:
Publication Number
WO/2025/109176
Publication Date
30.05.2025
International Application No.
PCT/EP2024/083304
International Filing Date
22.11.2024
Title **
[English]
OPTIMIZED SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS AND COMPOSITIONS COMPRISING THE SAME
[French]
LIANTS DE SOUS-UNITÉS DE SPICULE S2 DE SARBECOVIRUS OPTIMISÉS ET COMPOSITIONS LES COMPRENANT
Applicants **
EXEVIR BIO BV
VIB VZW
UNIVERSITEIT GENT
Inventors
BOCKSTAL, Viki
RINALDI, Manuela
VAN ROYEN, Tessa
BLANCHETOT, Christophe
VENNEMAN, Toon
CALLEWAERT, Nico
NERINCKX, Wim
SCHEPENS, Bert
DE CAE, Sieglinde
SAELENS, Xavier
VAN SCHIE, Loes
HERSCHKE, Florence
THOMAS, Antoine
Priority Data
23211603.8
22.11.2023
EP
24151698.8
12.01.2024
EP
24172808.8
26.04.2024
EP
24206518.3
14.10.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3517 | |
| EPO | Filing, Examination, Granting | 17747 | |
| Japan | Filing, Examination, Granting | 2521 | |
| South Korea | Filing, Examination, Granting | 2814 | |
| USA | Filing, Examination, Granting | 9240 |
Total:
35,839
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.[French]
La présente invention concerne des agents de liaison à Sarbecovirus, en particulier des anticorps et des fragments de liaison à l'antigène de ceux-ci, qui sont capables de neutraliser puissamment un Sarbecovirus, en particulier capables de neutraliser l'un quelconque ou les deux du SARS-CoV-2, y compris des variants du SARS-CoV-2, et du SARS-CoV-1, et des variants maturés par affinité de ceux-ci. Les agents de liaison, en particulier les anticorps et les fragments d'anticorps, ont une ou plusieurs caractéristiques favorables de développement d'anticorps. L'invention concerne également des procédés faisant appel à ces agents de liaison et leurs utilisations.